FightAcne.com Interview with:
Christopher J. Thang, BS
John Sealy School of Medicine
The University of Texas Medical Branch, Galveston
Department of Dermatology
Massachusetts General Hospital
Harvard Medical School, Boston
Jenny Lai, PhD
Harvard Medical School,
Department of Dermatology
Brigham and Women’s Hospital
Boston, Massachusetts
John S. Barbieri, MD, MBA, Senior Author
Department of Dermatology
Brigham and Women’s Hospital, Boston, Massachusetts
Associate Editor, JAMA Dermatology
FightAcne.com: What is the background for this study?
Response: Calcitonin gene-related peptide (CGRP) mediates neurogenic inflammation and vasodilation. Prior research has demonstrated increased CGRP expression in the skin of rosacea patients who experience flushing. CGRP signaling has also been implicated in acne pathogenesis. CGRP inhibitors are used for the prevention and treatment of migraines. We investigated whether CGRP inhibition for migraine patients is associated with a decreased risk of developing acne or rosacea.
FightAcne.com: What are the main findings?
Response: Using the TriNetX database, we found that those who were treated for migraine with monoclonal antibodies inhibiting CGRP had a decreased rate of acne and rosacea compared to matched controls who were treated with topiramate. Similar results were found compared to triptans and in sensitivity analyses requiring 2-years of follow-up.
FightAcne.com: What recommendations do you have for future research as a results of this study?
Response: Randomized controlled clinical trials are necessary to further examine the potential of CGRP inhibition for acne and rosacea. Our study also highlights that for those with migraines and comorbid rosacea, a CGRP inhibitor might be a more optimal treatment choice than other migraine therapies.
Disclosures: Dr. Barbieri reported grants from the National Institute of Arthritis and Musculoskeletal and Skin Diseases and personal fees from Dexcel Pharma outside the submitted work. No other disclosures reported.
Citation: Thang CJ, Lai J, Garate D, et al. Calcitonin Gene-Related Peptide Inhibition and Development of Acne and Rosacea. JAMA Dermatol. Published online July 10, 2024. doi:10.1001/jamadermatol.2024.2182
The information on FightAcne.com.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.